Industry Insights
Deep dives on clinical endpoints, regulatory trends and data quality — written and curated by the EClinCloud team.
FDA E2B(R3) in 2026: the routing decision that should come before an EDC rebuildSeparate FDA E2B(R3) reporting scope, ESG and SRP pathways, periodic-report reconciliation and the actual impact on clinical data capture.
FDA COA Evidence Dossier in 2026: A Planning Crosswalk and Draft-Status ReviewMap COA evidence to the September 2025 discussion draft, compare stakeholder requests and keep draft proposals separate from effective submission requirements.
FDA Study-Data Standards in 2026: Selecting Compatible VersionsRecheck FDA catalog support windows, compatible model and guide versions, terminology releases and study-start dates before finalizing your study-data specification.
FDA Investigator Records and Site Monitoring: What BMIS and Inspection Data Can SupportAn independently recomputed BMIS record audit, FDA inspection evidence and study-location analysis for site qualification and monitoring decisions.
FDA PFDD Guidance 3 and ClinicalTrials.gov 2026: PRO vs ClinRO Tokens, Patient-Reported Outcome Registration, and eCOA ImplementationFDA PFDD Guidance 3 is a fit-for-purpose selection file. ClinicalTrials.gov outcome text almost never stores COA type; PRO language is common and still not validation.
FDA Warning Letters, BIMO Computerized Systems and 21 CFR 312.62 Records in 2026: What Clinical Trial Data Integrity, Part 11 and eTMF Inspections Actually CiteFDA warning letters and BIMO observations cite investigator records and protocol compliance far more than EDC or eTMF products. Part 11 is not the dominant public inspection object.
From regulatory intent to practice: choosing a fit-for-purpose clinical outcome assessmentA practical overview of FDA PFDD Guidance 3, the four COA types, fit-for-purpose evidence, and how eCOA supports patient-focused endpoint implementation.